EyeYon Medical, Ltd.
EyeYon Medical is a pioneering company in ophthalmologic medical devices, dedicated to developing innovative solutions for corneal health. Their mission is to heal corneas and preserve the vision of millions of patients worldwide through advanced technologies like EndoArt® and Hyper-CL™.
Industries
Nr. of Employees
small (1-50)
EyeYon Medical, Ltd.
3 Golda Meir St., 6th floor, Ness Ziona 7403648 Israel
Patents
Products
EndoArt (artificial endothelial layer implant)
A flexible synthetic posterior corneal membrane implanted into the anterior chamber to act as a passive barrier to fluid transfer, intended to reduce corneal edema and restore corneal clarity.
Hyper-CL (therapeutic drug-depot contact lens)
A soft therapeutic contact lens with an integrated reservoir that captures topical eye drops against the cornea to extend drug contact time and promote corneal healing.
EndoArt (artificial endothelial layer implant)
A flexible synthetic posterior corneal membrane implanted into the anterior chamber to act as a passive barrier to fluid transfer, intended to reduce corneal edema and restore corneal clarity.
Hyper-CL (therapeutic drug-depot contact lens)
A soft therapeutic contact lens with an integrated reservoir that captures topical eye drops against the cornea to extend drug contact time and promote corneal healing.
Services
Design and execution of multicenter clinical studies, EDC-based data capture, study enrollment support, and clinical outcome analysis for ophthalmic devices.
Preparation of regulatory binders, marketing authorization submissions, and regional regulatory engagement (CE marking, FDA, NMPA) to support product approvals.
Training of surgeons on implantation techniques, intraoperative handling, and clinical implementation for novel corneal implants and therapeutic lenses.
Materials research and development for biocompatible sterile implants and contact lenses, including hydrogel formulations and controlled-release systems.
Verification and validation planning and execution, and coordination of in vitro and in vivo preclinical studies to support product development and submissions.
Design and execution of multicenter clinical studies, EDC-based data capture, study enrollment support, and clinical outcome analysis for ophthalmic devices.
Preparation of regulatory binders, marketing authorization submissions, and regional regulatory engagement (CE marking, FDA, NMPA) to support product approvals.
Training of surgeons on implantation techniques, intraoperative handling, and clinical implementation for novel corneal implants and therapeutic lenses.
Materials research and development for biocompatible sterile implants and contact lenses, including hydrogel formulations and controlled-release systems.
Verification and validation planning and execution, and coordination of in vitro and in vivo preclinical studies to support product development and submissions.
Expertise Areas
- Corneal implant development
- Ocular drug delivery and contact lens therapeutics
- Preclinical and clinical development for ophthalmic devices
- Regulatory affairs and submissions (CE, FDA, NMPA)
Key Technologies
- Synthetic thin-film implant membranes for endothelial replacement
- Therapeutic drug-depot soft contact lens with reservoir geometry
- Hydrogel and biomimetic nano‑polymer materials
- Minimally invasive intraocular implantation techniques
News & Updates
EyeYon Medical will be attending the 40th Congress of the ESCRS in Milan, showcasing their contributions to the event.
EyeYon Medical was featured in the media following the first EndoArt surgery in England, highlighting the positive impact on the patient's vision.
This publication discusses the successful treatment of neurotrophic keratopathy using Hyper-CL and insulin eye drops.
EndoArt received the Breakthrough Device Designation from the FDA, marking a significant milestone in its development.
EyeYon Medical will be attending the 40th Congress of the ESCRS in Milan, showcasing their contributions to the event.
EyeYon Medical was featured in the media following the first EndoArt surgery in England, highlighting the positive impact on the patient's vision.
This publication discusses the successful treatment of neurotrophic keratopathy using Hyper-CL and insulin eye drops.
EndoArt received the Breakthrough Device Designation from the FDA, marking a significant milestone in its development.